Regencell Bioscience Holdings Limited
RGC
$-0.35
Change (1 day)
$32.44
Year High
$3.03
Year Low
Categories
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
P/E ratio for Regencell Bioscience Holdings Limited (RGC)
P/E ratio as of 2023: -51.07
According to Regencell Bioscience Holdings Limited's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -51.07. At the end of 2022 the company had a P/E ratio of -60.66.
P/E ratio history for Regencell Bioscience Holdings Limited from 2002 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -51.07 |
| 2022 | -60.66 |
| 2021 | -98.57 |
| 2020 | -163.40 |
| 2019 | -339.50 |
| 2018 | 14.62 |
| 2017 | 9.66 |
| 2016 | 10.71 |
| 2015 | 15.44 |
| 2013 | 10.31 |
| 2012 | 11.18 |
| 2011 | 20.76 |
| 2010 | 16.83 |
| 2009 | 0.17 |
| 2007 | 0.17 |
| 2006 | 0.16 |
| 2005 | 18.42 |
| 2004 | 7.84 |
| 2002 | 12.65 |